Zachary Hartman

Daniel Nussbaum, MD, is one of 12 investigators to have been selected by National Cancer Institute for their Early-Stage Surgeon Scientist Program (ESSP).

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.

A DCI research team led by Zachary Hartman, PhD, has described a newly identified process for how the drug pertuzumab works in tandem with trastuzumab.

The metastatic breast cancer research grants, made possible by Susan G. Komen, bring together patient advocates and DCI & UNC Lineberger investigators.

DCI oncologists and researchers are supporting the Komen mission “for a cure” — fighting breast cancer on all fronts. Learn about their research.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Carey Anders, MD, and immunology researchers Erika Crosby, PhD, Zachary Hartman, PhD, among featured speakers at the national Komen MBC webinar series.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

Lyerly, Hartman spinout company Replicate Bioscience and Immunomic Therapeutics form collaboration to combat infectious diseases and cancers.

The mainstay drug trastuzumab could benefit from another antibody to remove roadblocks.